Nitin Jain elucidates the promising outcomes of the time-limited triplet therapy with pirtobrutinib, venetoclax, and obinutuzumab in first-line CLL treatment and addresses future challenges in clinical implementation. He shares recent advances in the development of more potent BTK inhibitors and depicts his personal highlights from this year’s EHA congress.

Here is the full EHA 2024 report.